GET THE APP

..

Journal of Immunobiology

ISSN: 2476-1966

Open Access

Current Issue

Volume 6, Issue 2 (2021)

    Editorial Pages: 1 - 2

    Cancer: All about a Minute Cell Which Multiplies in Numbers Making Loose Hope on Life

    Nicholas van Panhuys

    Cancer is a deadly disease which can be understood as the death of the cell, with no specific reasons known till today, the diagnosis of cancer can be done in certain stages where in initial stages it is unable to diagnose in some conditions. In other words cancer is also called as Malignancy. In today’s era there is a multiple mortality rate due to different types of cancer. Due to the unknown reason for the cause it affects all ages starting with neonates to the adultery .In some cases the cancer is cured and in some cases the treatment of the cancer may not bring out any results. Well coming to the cancer with additional diseases causing the disease to be more powerful than the will power of the human. There is no reason why it is affecting a specific person irrespective of age and gender. There are types of cancers like leukemia, brain tumor, osteomyelitis gastrointestinal cancer, Breast cancer etc. depending on the affected area the treatment varies some needed the radiotherapy and some require the removal of the tumor cell in order to affect their capacity to multiply. There are many advanced techniques in treatment of cancer like the surgeries and chemotherapy with additional medication. The chance of the life survival of a person after treatment depends on many conditions like the age and the personal health conditions some cancers can be treated with chemotherapy where the chance of survival can be predicted when coming to surgeries the chances are unpredicted. In adultery the treatment of cancer is a bit unpredicted where the already body aligning health conditions do not help the fast recovery or the recovery of cancer.

    Review Article Pages: 1 - 4

    Individualized Multimodal Immunotherapy for DIPG: Part of the Game?

    Stefaan W. van Gool*, Jennifer Makalowski, Tobias Sprenger, Volker Schirrmacher and Wilfried Stuecker

    In 2020 a study, entitled, Addition of multimodal immunotherapy to combination treatment strategies for children with Diffuse Intrinsic Pontine Glioma: A single institution experience was published in Medicines. The text reports the final analysis of 41 children treated with Individualized Multimodal Immunotherapy (IMI) as part of their (combined) treatment schedule. All these children came upon individual request or were referred by the physician to the Immune Oncologic Centre in Köln (www.iozk.de). Since May 2015, the IOZK has the official approval to produce under GMP conditions (DE_NW_04_GMP_2015_0030 and DE_NW_04_GMP_2020_0054) autologous Dendritic Cells (DCs) loaded with autologous tumor antigens and matured in the presence of IL-1b, IL-6 and TNF-a together with GMP-produced Newcastle Disease Virus (NDV). This Advanced Therapy Medicinal Product (ATMP), registered as IO-Vac®, is approved as medicinal product and as experimental medicinal product for use in human (DE_NW-04-MIA-2015-0033 and DE-NW-04-MIA-2020-0017). IO-Vac® is the drug used for active specific immunotherapy. IOZK is a private non-profit organization and delivers, besides 1) IO-Vac® DC vaccines, also 2) Immunogenic Cell Death (ICD) therapies with the Oncolytic Virus (OV) Newcastle Disease Virus (NDV) and modulated electro hyperthermia ,eventually inserted in chemotherapy regimens; 3) passive immunotherapy with antibodies, 4) modulatory immunotherapy with antibodies and/or low dose metronomic chemotherapy regimens and/or total body hyperthermia (brain lesions belong to exclusion criteria for this technology) and 5) finally a whole set of complementary medicinal strategies to improve immune reactivity.

    2021 Conference Announcement Pages: 1 - 1

    36th International Conference on Immunology, April 26-27, 2021

    Elizebth Marnon

    Conference Series invites all the participants across the world to attend 36th International Conference on Immunology to be held during April 26-27, 2021 which includes prompt keynote presentations, Oral talks, e-Poster presentations, Young Research Forum (YRF) and Exhibitions.

    Market Analysis Pages: 1 - 1

    International Conference on Immunology & Immunotherapies April 27, 2021

    Le Minh Sat

    Warm Welcome to all as we affably invite you to be a part of the International Conference on Immunology & Immunotherapies April 27, 2021 (Webinar). We invite all the participants from all across the globe to attend “Immunology & Immunotherapy” conference during April 27-2021 Webinar which includes prompt keynote presentations, poster and oral talks. This conference plays a Global platform for biomedical companies, clinical research divisions, professionals, specialists, consultants, doctors, scholars and students to frame a new relationship and build up the Knowledge. This is a wonderful opportunity for all the delegates to interact with the top grade world class Scientists. The particular members can confirm their participation through Registrations.

    2021 Conference Announcement Pages: 1 - 1

    Tumor & Cancer Immunology and Pediatric-Oncology April 15-16, 2021

    Elizebth Marnon

    With members from around the world focused on learning about Tumor and Cancer immunology and its advances: this is your best opportunity to reach the largest assemblage of participants from Tumor & Cancer immunology community. conduct presentations, distribute information’s, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event, world-renowned speakers, the most recent techniques, developments, and the newest updates in Tumor & Cancer immunology are hallmarks of this conference.

    Volume 6, Issue 4 (2021)

      Commentary Pages: 1 - 2

      The Broad Biological Significance of Eicosanoids in Invertebrates

      David Stanley and Yonggyun Kim*

      We present a brief sketch of the discovery of prostaglandins and other eicosanoids in human and veterinary biomedicine, and then comment on their significance in invertebrates, all reviewed in detail elsewhere. Here we bring out a few points. One, PG biosynthesis in insects follows a mechanism different from mammals. Two, insect systems are amenable to functional studies of specific genes operating in eicosanoid systems via RNAi and CRISPR-Cas9, which has accelerated understanding of genes involved in PG synthesis and in receptor-mediated actions. We suggest research into some model insect systems, particularly Drosophila melanogaster and the moth Spodoptera exigua, may lead to broadly useful insights into PG actions.

      Volume 7, Issue 4 (2022)

        Research Article Pages: 1 - 5

        Immunological Study for Helicobacter pylori Bacteria in Human

        Samuel Tanas Melek*, Mohamed H Yassin, Mohamed E Rashed and Taghreed A Zidan

        DOI: 10.37421/2476-1966.2022.7.180

        Helicobacter pylorus is one of the most important human pathogens, infecting more than 50% of the human population. Commonly the first noninvasively testes used for H. pylori infection's detection were immunological tests like blood antibody test and stool antigen test. We investigated the more efficient susceptibility immunological test for detection of H.pylori infection in adult Egyptian patients by comparing the results of H. pylori IgA (HpIgA), IgG in serum blood (HpIgG) and H.pylori Ag in stool (HpSAg) for 30 adult patient (males and females) against control group using ELISA technique.The results showed that each test could be used successfully for diagnosis of H. pylori with 100% specificity and PPV% with no gender relation. Finally HpSAg showed reliable results with high sensitivity (>95%) followed by HpIgG (87.5%), while HpIgA showed the lowest sensitivity (37.5%). Our findings confirms the use of the mentioned immunological tests for detectingthe H. pylori infection and suggest the use H. pylori Ag in stool as the most economic, sensitive and reliable method alone or followed by IgG antibody test as confirmatory test to be the first choices for early diagnosis of H. pylori especially in developing countries.

        Research Article Pages: 1 - 13

        IL-13 and STAT 6 Gene Variants and Atopic Disorders-A Case Control study from the Northern State of India

        Syed Mudassar*, Taha Ashraf Qurashi, Gulzar Ahmad Bhat, Mosin Saleem Khan and Roohi Rasool

        DOI: 10.37421/2476-1966.2022.7.181

        Inflammatory markers are considered as a common biochemical manifestation among subjects with atopic disorders. The current study was aimed to study the possible association of IL-13 and STAT 6 genes among atopic subjects.

        A total of 528 patients diagnosed with atopy and 610 normal subjects were taken for the polymorphic analysis of IL-13 and STAT 6 genes. On stratification, we observed a significant difference between cases and controls with various demographic, life style and dietary factors. Subjects harboring homozygous variant genotypes of IL-13–C1055 T and IL-13–A1512 C showed a statistically significant increase in atopy (OR=1.8 (1.2–2.6), P=0.001) and (OR=6.7 (4.9-9.2), P<0.0001) respectively. Similarly, the variant genotype of STAT 6 G2964 A showed a substantial increase towards atopy when harbor by the subjects (OR=3.7 (2.7–5.1), P<0.0001). Additionally, the above genetic variants of all the genes significantly modified the risk of allergy when stratification was done on the basis of various lifestyle, epidemiological and clinico-pathological characteristics.

        Mini Review Pages: 1 - 3

        Cutaneous Wound Healing By Antibodies to Injured Tissue

        Jameson Frankel*

        DOI: 10.37421/2476-1966.2022.7.183

        The process of healing a wound involves an extremely well-ordered series of actions, including hemostasis, inflammatory cell infiltration, tissue regeneration, and remodelling. Following tissue destruction, wound healing occurs, thus we reasoned that antibodies might bind to injured tissues, facilitating the engulfment of damaged tissues by macrophages. Here, we demonstrate how B cells participate in wound healing by secreting antibodies against injured tissues. Transfer of spleen cells into splenectomized mice reversed the delay in wound healing caused by splenectomy. Additionally, splenectomized nude mice showed a delay in wound healing. Magnetic beads used to transfer enhanced B220+ cells sped up the healing process in mice with splenectomies. Magnetic beads used to transfer enhanced B220+ cells sped up the healing process in mice with splenectomies. Using anti-IgG1 that has been fluorescein isothiocyanate-labeled, we were able to identify immunoglobulin G1 (IgG1) binding to injured tissues 6–24 hours after the injury. The amount of IgG1 binding to injured tissues was decreased after splenectomy. Studies using immunoblotting showed multiple bands, which were diminished following splenectomy. We discovered that the strength of numerous bands was lower in the serum from splenectomized animals than in that from mice who underwent a sham operation using immunoprecipitation with anti-IgG linked to protein G.

      Relevant Topics

arrow_upward arrow_upward